Status:
COMPLETED
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Anemia, Sickle Cell
Eligibility:
All Genders
2-7 years
Brief Summary
Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with ...
Detailed Description
SCA is an inherited blood disorder in which the body makes sickle-shaped red blood cells that contain abnormal hemoglobin. The sickled cells block blood flow in the vessels that lead to limbs and orga...
Eligibility Criteria
Inclusion
- All children who completed at least 18 months of follow-up visits in the initial BABY HUG study
- Children from the initial BABY HUG study who are on a chronic transfusion program or who are recipients of a bone marrow transplant
Exclusion
- Any child who was not enrolled in the initial BABY HUG study for at least 18 months
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00890396
Start Date
September 1 2008
End Date
December 1 2011
Last Update
August 20 2020
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010
3
Howard University College of Medicine
Washington D.C., District of Columbia, United States, 20060
4
University of Miami School of Medicine
Miami, Florida, United States, 33136